Minerva Neurosciences Inc. (Nasdaq: NERV) reported positive results from a Phase IIb trial of MIN-101 to treat patients with negative symptoms of schizophrenia. Shares of the biopharmaceutical nearly tripled by leaping $6.76 to $10.30.